Answers are grounded in this paper and cite their sources.
Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments.
No takes yet. Share an insight, caveat, or question.
Passeron et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: